Who is sponsoring NCT06853522?

NCT06853522 is sponsored by Shanghai East Hospital.

What condition does NCT06853522 study?

NCT06853522 studies Ulcerative Colitis (UC).

Is NCT06853522 still recruiting?

NCT06853522 is currently not yet recruiting. Last updated 27 April 2025.

Last reviewed 2025-04-27 · How we verify

NCT06853522

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

hucMSCs Exosomes for the Treatment of Active Ulcerative Colitis

Not yet recruiting EARLY_PHASE1 Last updated 27 April 2025

What this trial tests

EARLY_PHASE1 trial testing exosomes derived from human umbilical cord mesenchymal stem cells in Ulcerative Colitis (UC) in 40 participants. Not yet recruiting.

Timeline

30 May 2025

Primary endpoint
4 April 2027

4 April 2028

Quick facts

Lead sponsor	Shanghai East Hospital
Phase	EARLY_PHASE1
Status	Not yet recruiting
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	40
Start date	30 May 2025
Primary completion	4 April 2027
Estimated completion	4 April 2028
Sites	1 location across China

Drugs / interventions tested

exosomes derived from human umbilical cord mesenchymal stem cells — full drug profile →
saline +5% albumin — full drug profile →

Conditions studied

Ulcerative Colitis (UC) — all drugs for Ulcerative Colitis (UC) →

Sponsor

Shanghai East Hospital

Who can join

Adults 18 to 75, any sex, with Ulcerative Colitis (UC). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To evaluate the safety and efficacy of hUC-MSCs-Exos in the treatment of ulcerative colitis.

Publications & conference data

5 peer-reviewed publications reference this trial (live from Europe PMC):

Exosome-Based Drug Delivery: A Next-Generation Platform for Cancer, Infection, Neurological and Immunological Diseases, Gene Therapy and Regenerative Medicine.
Serrano DR, Juste F, Anaya BJ, Ramirez BI, et al · · 2025 · cited 27× · PMID 41155971 · DOI 10.3390/pharmaceutics17101336
Biological Nanotherapeutics Derived From Human Umbilical Cord Mesenchymal Stem Cells: Mechanisms and Translational Potential in Multisystem Therapies for Regeneration and Oncology.
Zhang R, Xu Z, Xu S, Li R, et al · · 2025 · cited 3× · PMID 41078403 · DOI 10.2147/ijn.s550390
Stem Cell Therapies for Gastrointestinal and Liver Diseases: Translational Barriers, Clinical Heterogeneity, and Future Directions.
Nikolaev G, Lozenov S, Konaktchieva M, Arabadzhiev B, et al · · 2026 · PMID 42193425 · DOI 10.3390/biomedicines14051102
The roles and clinical applications of mesenchymal stem cells and their exosomes in hematologic diseases.
Deng M, Zhang X, Zhang Y. · · 2025 · PMID 41444972 · DOI 10.1186/s13287-025-04880-8
Endoplasmic reticulum stress and exosomes secretion in the pathogenesis of inflammatory bowel disease: a concise summary of research findings.
Shibili P A, Banerjee A, Chakraborty S, Kondaveeti SB, et al · · 2025 · PMID 41383462 · DOI 10.3389/fphar.2025.1702825

Verify or expand the search:

Other recruiting trials for Ulcerative Colitis (UC)

Currently open trials in the same condition.

NCT07335055 — A Study for HSK47388 in Participants With Ulcerative Colitis · Phase 2 · recruiting
NCT07271069 — Effectiveness of Ozanimod in Patients With Steroid-Dependent Ulcerative Colitis · recruiting
NCT07245394 — Switching to the IL-23 Inhibitor Guselkumab for People With Active IBD Who Previously Used Ustekinumab (SHIFT-IBD) · recruiting
NCT07237516 — Zymfentra (Infliximab-dyyb) REal World Cohort STudy · recruiting
NCT07350577 — Evaluate the Safety, Tolerability, PK and PD of SAD of Intravenously Adminsterted ALTB-268 in Healthy Participants · Phase 1 · recruiting

Other Shanghai East Hospital trials

Trials by the same sponsor.

NCT07519161 — Pharmacological Intervention to Prevent NOAF After TAVR · NA · not yet recruiting
NCT07516223 — MRI-Assisted Guidance for Non-Essential Tissue Sampling · NA · not yet recruiting
NCT07279259 — Thrombolysis in Early Acute Ischemic Stroke Trial-Blood Pressure Management · Phase 2 · recruiting
NCT07294495 — Effect of Henagliflozin on Myocardial Fibrosis in Non-Obstructive HCM: A Randomized, Double-Blind, Placebo-Controlled Tr · NA · not yet recruiting
NCT07290816 — Effect of Non-invasive Neuromodulation on the Quality of Intestinal Cleansing · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06853522 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Shanghai East Hospital
Last refreshed: 27 April 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06853522.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing